Pancreatic Mucinous-Cystic Neoplasm
Associated Genetic Biomarkers
NCI Definition: A non-invasive or invasive cystic epithelial neoplasm that affects almost exclusively females. It is characterized by the presence of columnar mucin-producing epithelial cells and ovarian-type stroma formation. 
Pancreatic mucinous-cystic neoplasms most frequently harbor alterations in TP53, KRAS, RNF43, PIK3CA, and TMEM127 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and PIK3CA Mutation are the most common alterations in pancreatic mucinous-cystic neoplasm .
There is 1 clinical trial for pancreatic mucinous-cystic neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains pancreatic mucinous-cystic neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
ATM, ATR, and BARD1 are the most frequent gene inclusion criteria for pancreatic mucinous-cystic neoplasm clinical trials .
Gemcitabine, modified folfirinox regimen, and nab-paclitaxel are the most common interventions in pancreatic mucinous-cystic neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.